Select Publications
Ang K et al. A Phase III trial to compare standard versus accelerated fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): Report of compliance and toxicity. Proc ASTRO 2007;Abstract 21.
Bonner JA et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78. Abstract
Curran D et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007;25(16):2191-7. Abstract
The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324(24):1685-90. Abstract
Jensen AD et al. Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: The NEAR protocol (NCT00115518). BMC Cancer 2006;6:122. Abstract
Pfister DG et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24(7):1072-8. Abstract
Posner MR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-15. Abstract
Staar S et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy — Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50(5):1161-71. Abstract
Vermorken JB et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695-704. Abstract
|
